TriSalus Life Sciences (NASDAQ:TLSI) Price Target Lowered to $11.00 at Canaccord Genuity Group

TriSalus Life Sciences (NASDAQ:TLSI) had its target price trimmed by Canaccord Genuity Group from $12.00 to $11.00 in a report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

TLSI has been the subject of several other research reports. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Roth Mkm assumed coverage on TriSalus Life Sciences in a report on Monday, November 11th. They set a “buy” rating and a $11.00 price target on the stock. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Finally, Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Stock Down 2.0 %

Shares of NASDAQ:TLSI traded down $0.08 during midday trading on Friday, reaching $3.93. The company’s stock had a trading volume of 27,024 shares, compared to its average volume of 38,374. TriSalus Life Sciences has a twelve month low of $3.32 and a twelve month high of $10.42. The firm has a market capitalization of $119.83 million, a PE ratio of -1.57 and a beta of 0.49. The stock has a fifty day moving average of $4.33 and a 200 day moving average of $5.80.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million during the quarter. Sell-side analysts anticipate that TriSalus Life Sciences will post -1.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mary T. Szela bought 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $5.20 per share, with a total value of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at $1,962,386.40. The trade was a 2.03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Duquesne Family Office LLC raised its position in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in TriSalus Life Sciences in the 2nd quarter valued at $1,184,000. Geode Capital Management LLC boosted its position in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the period. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences in the second quarter worth $240,000. Finally, MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the 3rd quarter worth about $184,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.